(Q36598110)

15 August 2017

1 reference

title

Exenatide: a new option for the treatment of type 2 diabetes (English)

1 reference

15 August 2017

1 reference

Bong Kyu Yoo

1

1 reference

15 August 2017

Darren Michael Triller

series ordinal

2

1 reference

15 August 2017

Dong Joo Yoo

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

19 September 2006

1 reference

Annals of Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

40

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1777-1784

1 reference

Bioactive peptides from lizard venoms

15 August 2017

cites work

1 reference

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

Incretin mimetics as emerging treatments for type 2 diabetes

21 January 2018

1 reference

Triggering and amplifying pathways of regulation of insulin secretion by glucose

21 January 2018

1 reference

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

21 January 2018

1 reference

Effect of exenatide on the steady-state pharmacokinetics of digoxin.

21 January 2018

1 reference

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

21 January 2018

1 reference

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H060

1 reference

15 August 2017

1 reference